Москва 125252, ул. Алабяна 13, корпус 1
+7 (495) 098-03-59
Заказать звонок
  • О портале
  • Контакты
  • ...
    Omnidoctor
    Библиотека
    • Издания для врачей
      • Consilium Medicum
      • Педиатрия.Consilium Medicum
      • Современная Онкология
      • Гинекология
      • Терапевтический архив
      • Газета «Участковый терапевт»
      • Газета «Женская консультация»
      • Газета «Участковый педиатр»
      • Справочник поликлинического врача
      • Cardioсоматика
      • Системные гипертензии
    • Издания для провизоров и фармацевтов
      • Газета «Первостольник»
      • Справочник провизора
    • Online-издания
      • Женская консультация
      • Участковый педиатр
      • Участковый терапевт
    Медиатека
    Мероприятия
    Спецпроекты
    • ИммуноГалактика (NEW!)
    • Гормональный оркестр
    • CardioSPACE
    • NeuroFusion (NEW!)
    • Современная Онкология
    • Урологика
    Пресс-центр
    Практикум
      Библиотека
      Медиатека
      Мероприятия
      Спецпроекты
      ИммуноГалактика (NEW!)
      Гормональный оркестр
      CardioSPACE
      NeuroFusion (NEW!)
      Современная Онкология
      Урологика
      Пресс-центр
      Практикум
      Omnidoctor
      Библиотека
      • Издания для врачей
        • Consilium Medicum
        • Педиатрия.Consilium Medicum
        • Современная Онкология
        • Гинекология
        • Терапевтический архив
        • Газета «Участковый терапевт»
        • Газета «Женская консультация»
        • Газета «Участковый педиатр»
        • Справочник поликлинического врача
        • Cardioсоматика
        • Системные гипертензии
      • Издания для провизоров и фармацевтов
        • Газета «Первостольник»
        • Справочник провизора
      • Online-издания
        • Женская консультация
        • Участковый педиатр
        • Участковый терапевт
      Медиатека
      Мероприятия
      Спецпроекты
      • ИммуноГалактика (NEW!)
      • Гормональный оркестр
      • CardioSPACE
      • NeuroFusion (NEW!)
      • Современная Онкология
      • Урологика
      Пресс-центр
      Практикум
        Omnidoctor
        • Библиотека
          • Назад
          • Библиотека
          • Издания для врачей
            • Назад
            • Издания для врачей
            • Consilium Medicum
            • Педиатрия.Consilium Medicum
            • Современная Онкология
            • Гинекология
            • Терапевтический архив
            • Газета «Участковый терапевт»
            • Газета «Женская консультация»
            • Газета «Участковый педиатр»
            • Справочник поликлинического врача
            • Cardioсоматика
            • Системные гипертензии
          • Издания для провизоров и фармацевтов
            • Назад
            • Издания для провизоров и фармацевтов
            • Газета «Первостольник»
            • Справочник провизора
          • Online-издания
            • Назад
            • Online-издания
            • Женская консультация
            • Участковый педиатр
            • Участковый терапевт
        • Медиатека
        • Мероприятия
        • Спецпроекты
          • Назад
          • Спецпроекты
          • ИммуноГалактика (NEW!)
          • Гормональный оркестр
          • CardioSPACE
          • NeuroFusion (NEW!)
          • Современная Онкология
          • Урологика
        • Пресс-центр
        • Практикум
        • Мой кабинет
        • +7 (495) 098-03-59
        Москва 125252, ул. Алабяна 13, корпус 1
        info@omnidoctor.ru
        • Вконтакте
        • Telegram
        • YouTube
        • Главная
        • Библиотека
        • Издания для врачей
        • Терапевтический архив
        • Журнал Терапевтический архив 2021 Терапевтический архив
        • Журнал Терапевтический архив №2 Вопросы гастроэнтерологии 2021
        • Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала - Журнал Терапевтический архив №2 Вопросы гастроэнтерологии 2021

        Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала - Журнал Терапевтический архив №2 Вопросы гастроэнтерологии 2021

        Якупова А.А., Абдулхаков С.Р., Сафин А.Г. и др. Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала (обзор современных рекомендаций). Терапевтический архив. 2021; 93 (2): 215–221. DOI: 10.26442/00403660.2021.02.200615

        ________________________________________________

         Iakupova А.А., Abdulkhakov S.R., Safin A.G., et al. Fecal microbiota transplantation: donor selection criteria, storage and preparation of biomaterials (review of current recommendations). Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (2): 215–221. DOI: 10.26442/00403660.2021.02.200615

        Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала

        Якупова А.А., Абдулхаков С.Р., Сафин А.Г. и др. Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала (обзор современных рекомендаций). Терапевтический архив. 2021; 93 (2): 215–221. DOI: 10.26442/00403660.2021.02.200615

        ________________________________________________

         Iakupova А.А., Abdulkhakov S.R., Safin A.G., et al. Fecal microbiota transplantation: donor selection criteria, storage and preparation of biomaterials (review of current recommendations). Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (2): 215–221. DOI: 10.26442/00403660.2021.02.200615

        • Читать PDF
          Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала

        Материалы доступны только для специалистов сферы здравоохранения.
        Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

        • Аннотация
        • Список литературы
        • Авторы
        Аннотация
        реципиенту с целью восстановления нарушенного состава микробиоты кишечника. На сегодняшний день в лечении ряда заболеваний проводятся попытки применения ТФМ. В данном обзоре проведена попытка систематизации имеющихся на сегодняшний день данных, касающихся определения показаний для проведения ТФМ, рекомендаций по отбору доноров, сбору, обработке и хранению донорского биоматериала.

        Ключевые слова: трансплантация фекальной микробиоты, критерии отбора доноров, микробиота кишечника

        ________________________________________________

        Fecal microbiota transplantation is a treatment method based on the introduction of donated fecal material to the recipient in order to restore the damaged composition of the intestinal microbiota. This review summarizes existing data on indications for fecal microbiota transplantation, recommendations for donor selection, processing and storage of donor biomaterial.

        Keywords: fecal microbiota transplantation, donor selection criteria, gut microbiota

        Список литературы
        1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80. doi: 10.1136/gutjnl-2016-313017
        2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-15. doi: 10.1056/NEJMoa1205037
        3. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142-9. doi: 10.1001/jama.2015.18098
        4. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med. 2016;165:609-16. doi: 10.7326/M16-0271
        5. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-43. doi: 10.1111/apt.13144
        6. Hvas CL, Dahl Jorgensen SM, Jorgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156:1324-32. doi: 10.1053/j.gastro.2018
        7. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection. JAMA. 2017;318:1985-93. doi: 10.1001/jama.2017
        8. Cammarota G, Ianiro G, Magalini S, et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163:487-8. doi: 10.7326/L15-5139
        9. Fischer M, Sipe B, Cheng Y-W, et al. Fecal microbiota transplant in severe and severe complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289-302. doi: 10.1080/19490976.2016.1273998
        10. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470-6. doi: 10.1111/apt.13290
        11. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47:735-7. 
        doi: 10.1097/MCG.0b013e31829004ae
        12. Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152-9. doi: 10.1111/apt.14816
        13. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-9. doi: 10.1053/j.gastro.2015.04.001
        14. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. JAMA. 2019;321:156-64. doi: 10.1001/jama.2018.20046
        15. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomized placebo controlled trial. Lancet. 2017;389:1218-28. 
        doi: 10.1016/S0140-6736(17)30182-4
        16. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-8. doi: 10.1053/j.gastro.2015.03.045
        17. Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213-24. doi: 10.1111/apt.14173
        18. Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23:1702-9. doi: 10.1097/MIB.0000000000001228
        19. Scaldaferri F, Pecere S, Petito V, et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis. Transplant Proc. 2016;48:402-7. doi: 10.1016/j.transproceed.2015.12.040
        20. Ianiro G, Bibbò S, Scaldaferri F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):97. doi: 10.1097/MD.0000000000000097
        21. Sood A, Mahajan R, Singh A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13(10):1311-7. doi: 10.1093/ecco-jcc/jjz060
        22. Щербаков П.Л., Белова Н.Д., Генерозов Э.В. и др. Применение фекальной трансплантации в лечении заболеваний пищевари­тельного тракта (первый клинический опыт). Доктор.Ру. 2019;3(158):40-6 [Scherbakov PL, Belova ND, Generozov EV, et al. Faecal Transplant in GIT Treatment (Pilot Clinical Experience). Doctor.Ru. 2019;3(158):40-6 (In Russ.)]. doi: 10.31550/1727-2378-2019-158-3-40-46
        23. Halkjaer SI, Christensen AH, Lo BZ, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomized, double-blind placebo-controlled study. Gut. 2018;67(12):2107-15. doi: 10.1136/gutjnl-2018-316434
        24. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-center trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2
        25. Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome. Clin Transl Gastroenterol. 2019;10(4):e00034. 
        doi: 10.14309/ctg.0000000000000034
        26. Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50:240-8. doi: 10.1111/apt.15330
        27. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727-38. doi: 10.1002/hep.29306
        28. Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic‐associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology. 2018;68:1549-58. doi: 10.1002/hep.30037
        29. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6. doi: 10.1053/j.gastro.2012.06.031
        30. Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611-9. 
        doi: 10.1016/j.cmet.2017.09.008
        31. Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65:364-70. doi: 10.1093/cid/cix252
        32. Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect. 2019;25:830-8. doi: 10.1016/j.cmi.2018.12.009
        33. Kuijper EJ, Vendrik KEW, Vehreschild MJGT. Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract. Clin Microbiol Infect. 2019;25:786-9. 
        doi: 10.1016/j.cmi.2019.03.025
        34. Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071-9. doi: 10.14309/ajg.0000000000000115
        35. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5. doi: 10.1186/s40168-016-0225-7
        36. Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804-8. doi: 10.1038/s41591-018-0238-9
        37. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91-7. doi: 10.1126/science.aan3706
        38. Youlian Z, Haoming X, Hongli H, et al. Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? Hindawi BioMed Res Int Vol. 2019;1-11. doi: 10.1155.2019.3469754
        39. Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Inf. 2017;23(12):924-30. doi: 10.1016/j.cmi.2017.05.015
        40. Mullish BH, Quraishi M, Segal J, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;0:1-22. doi: 10.1136/gutjnl-2018-316818
        41. Kump P, Krause R, Steininger C, et al. Empfehlungenzur Anwendung der fäkalen Mikrobiotatransplantation „Stuhltransplantation“: Konsensus der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeitmit der Österreichischen Gesellschaftfür Infektiologie und Tropenmedizin (OEGIT). Z Gastroenterol. 2014;52:1485-92. doi: 10.1055/s-0034-1385562
        42. Cammarota G, Ianiro G, Kelly CR, Mullish BH, et al. International consensus conference on stool banking for faecalmicrobiota transplantation in clinical practice. Gut. 2019;68:2111-21. doi: 10.1136/gutjnl-2019-319548
        43. OpenBiome. OpenBiome Quality Metrics. 2019. Available at: https://static1.squarespace.com/static/50e0c29ae4b0a05702af7e6a/t/5cc2477b36a72a000152b793/1556236156464/Quality+Metrics.pdf
        44. Kassam Z, Dubois NE, Ling K. 512 – donor health screening for fecal microbiota transplantation: prospective evaluation of 15,317 candidate donors. Gastroenterology. 2019;156:100-1. doi: 10.1016/S0016-5085(19)37042-8
        45. Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600-6. doi: 10.1097/MIB.0000000000000405
        46. Food and Drug Administration. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation – screening and testing of stool donors for multi-drug resistant organisms. 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-ad...
        47. Chu ND, Smith MB, Perrotta AR, et al. Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS One. 2017. 26;12(1):e0170922. doi: 10.1371/journal.pone.0170922
        48. Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecalmicrobiota transplantation for recurrent Clostridium difficile infection – an observational cohort study. Aliment Pharmacol Ther. 2015;41:46-53. doi: 10.1111/apt.13009
        49. Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-6. doi: 10.1053/j.gastro.2011.11.037
        50. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515-22. doi: 10.1093/cid/ciu135
        51. Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015;42:1011-8. doi: 10.1111/apt.13366
        52. Adair A, Wigmore SJ. Paid organ donation: the case against. Annals. 2011;93:191-2. doi: 10.1308/147870811X565061a
        53. Elliott RJ, Nienga M, Ladha A, et al. Stool processing speed and storage duration do not impact clinical effectiveness of fecal microbiota transplantation across 1,924 Clostridium difficile infection patients. Am J Gastroenterol. 2016;111. doi: 10.14309/00000434-201610001-00119
        54. Budree S, Elliott RJ, Rao S, et al. Donor stool processing time: the effect on the intestinal microbiome and clinical outcomes of fecal microbiota transplantation in Clostridium difficile infection. Gastroenterology. 2017;152:1006. doi: 10.1016/S0016-5085(17)33415-7
        55. Bahl MI, Bergström A, Licht TR. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiol Lett. 2012;329:193-7. doi: 10.1111/j.1574-6968.2012.02523.x
        56. Sleight SC, Wigginton NS, Lenski RE. Increased susceptibility to repeated freeze-thaw cycles in Escherichia coli following long-term evolution in a benign environment. BMC Evol Biol. 2006;6:104. 
        doi: 10.1186/1471-2148-6-10457. Long C, Yu Y, Cui B, et al. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol.2018;18:37. doi: 10.1186/s12876-018-0766-2
        58. Shi Y, Dong Y, Huang W, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Public Library of Science ONE. 2016:11(6):e0157259. doi: 10.1371/ journal.pone.0157259
        59. Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016, 4: 610-3. doi: 10.1055/s-0042-105205
        60. Osman M, O’Brien K, Stoltzner Z, et al. Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis. 2016;3. doi: 10.1093/ofid/ofw172.1668
        61. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-8. doi: 10.1038/ajg.2013.59
        62. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic 
        review. J Clin Gastroenterol. 2014;48:693-702. doi: 10.1097/MCG.0000000000000046

        ________________________________________________

        1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80. doi: 10.1136/gutjnl-2016-313017
        2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-15. doi: 10.1056/NEJMoa1205037
        3. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142-9. doi: 10.1001/jama.2015.18098
        4. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med. 2016;165:609-16. doi: 10.7326/M16-0271
        5. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-43. doi: 10.1111/apt.13144
        6. Hvas CL, Dahl Jorgensen SM, Jorgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156:1324-32. doi: 10.1053/j.gastro.2018
        7. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection. JAMA. 2017;318:1985-93. doi: 10.1001/jama.2017
        8. Cammarota G, Ianiro G, Magalini S, et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163:487-8. doi: 10.7326/L15-5139
        9. Fischer M, Sipe B, Cheng Y-W, et al. Fecal microbiota transplant in severe and severe complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289-302. doi: 10.1080/19490976.2016.1273998
        10. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470-6. doi: 10.1111/apt.13290
        11. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47:735-7. 
        doi: 10.1097/MCG.0b013e31829004ae
        12. Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152-9. doi: 10.1111/apt.14816
        13. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-9. doi: 10.1053/j.gastro.2015.04.001
        14. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. JAMA. 2019;321:156-64. doi: 10.1001/jama.2018.20046
        15. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomized placebo controlled trial. Lancet. 2017;389:1218-28. 
        doi: 10.1016/S0140-6736(17)30182-4
        16. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-8. doi: 10.1053/j.gastro.2015.03.045
        17. Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213-24. doi: 10.1111/apt.14173
        18. Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23:1702-9. doi: 10.1097/MIB.0000000000001228
        19. Scaldaferri F, Pecere S, Petito V, et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis. Transplant Proc. 2016;48:402-7. doi: 10.1016/j.transproceed.2015.12.040
        20. Ianiro G, Bibbò S, Scaldaferri F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):97. doi: 10.1097/MD.0000000000000097
        21. Sood A, Mahajan R, Singh A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13(10):1311-7. doi: 10.1093/ecco-jcc/jjz060
        22. Scherbakov PL, Belova ND, Generozov EV, et al. Faecal Transplant in GIT Treatment (Pilot Clinical Experience). Doctor.Ru. 2019;3(158):40-6 (In Russ.) doi: 10.31550/1727-2378-2019-158-3-40-46
        23. Halkjaer SI, Christensen AH, Lo BZ, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomized, double-blind placebo-controlled study. Gut. 2018;67(12):2107-15. doi: 10.1136/gutjnl-2018-316434
        24. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-center trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2
        25. Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome. Clin Transl Gastroenterol. 2019;10(4):e00034. 
        doi: 10.14309/ctg.0000000000000034
        26. Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50:240-8. doi: 10.1111/apt.15330
        27. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727-38. doi: 10.1002/hep.29306
        28. Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic‐associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology. 2018;68:1549-58. doi: 10.1002/hep.30037
        29. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6. doi: 10.1053/j.gastro.2012.06.031
        30. Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611-9. 
        doi: 10.1016/j.cmet.2017.09.008
        31. Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65:364-70. doi: 10.1093/cid/cix252
        32. Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect. 2019;25:830-8. doi: 10.1016/j.cmi.2018.12.009
        33. Kuijper EJ, Vendrik KEW, Vehreschild MJGT. Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract. Clin Microbiol Infect. 2019;25:786-9. 
        doi: 10.1016/j.cmi.2019.03.025
        34. Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071-9. doi: 10.14309/ajg.0000000000000115
        35. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5. doi: 10.1186/s40168-016-0225-7
        36. Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804-8. doi: 10.1038/s41591-018-0238-9
        37. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91-7. doi: 10.1126/science.aan3706
        38. Youlian Z, Haoming X, Hongli H, et al. Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? Hindawi BioMed Res Int Vol. 2019;1-11. doi: 10.1155.2019.3469754
        39. Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Inf. 2017;23(12):924-30. doi: 10.1016/j.cmi.2017.05.015
        40. Mullish BH, Quraishi M, Segal J, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;0:1-22. doi: 10.1136/gutjnl-2018-316818
        41. Kump P, Krause R, Steininger C, et al. Empfehlungenzur Anwendung der fäkalen Mikrobiotatransplantation „Stuhltransplantation“: Konsensus der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeitmit der Österreichischen Gesellschaftfür Infektiologie und Tropenmedizin (OEGIT). Z Gastroenterol. 2014;52:1485-92. doi: 10.1055/s-0034-1385562
        42. Cammarota G, Ianiro G, Kelly CR, Mullish BH, et al. International consensus conference on stool banking for faecalmicrobiota transplantation in clinical practice. Gut. 2019;68:2111-21. doi: 10.1136/gutjnl-2019-319548
        43. OpenBiome. OpenBiome Quality Metrics. 2019. Available at: https://static1.squarespace.com/static/50e0c29ae4b0a05702af7e6a/t/5cc2477b36a72a000152b793/1556236156464/Quality+Metrics.pdf
        44. Kassam Z, Dubois NE, Ling K. 512 – donor health screening for fecal microbiota transplantation: prospective evaluation of 15,317 candidate donors. Gastroenterology. 2019;156:100-1. doi: 10.1016/S0016-5085(19)37042-8
        45. Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600-6. doi: 10.1097/MIB.0000000000000405
        46. Food and Drug Administration. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation – screening and testing of stool donors for multi-drug resistant organisms. 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-ad...
        47. Chu ND, Smith MB, Perrotta AR, et al. Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS One. 2017. 26;12(1):e0170922. doi: 10.1371/journal.pone.0170922
        48. Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecalmicrobiota transplantation for recurrent Clostridium difficile infection – an observational cohort study. Aliment Pharmacol Ther. 2015;41:46-53. doi: 10.1111/apt.13009
        49. Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-6. doi: 10.1053/j.gastro.2011.11.037
        50. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515-22. doi: 10.1093/cid/ciu135
        51. Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015;42:1011-8. doi: 10.1111/apt.13366
        52. Adair A, Wigmore SJ. Paid organ donation: the case against. Annals. 2011;93:191-2. doi: 10.1308/147870811X565061a
        53. Elliott RJ, Nienga M, Ladha A, et al. Stool processing speed and storage duration do not impact clinical effectiveness of fecal microbiota transplantation across 1,924 Clostridium difficile infection patients. Am J Gastroenterol. 2016;111. doi: 10.14309/00000434-201610001-00119
        54. Budree S, Elliott RJ, Rao S, et al. Donor stool processing time: the effect on the intestinal microbiome and clinical outcomes of fecal microbiota transplantation in Clostridium difficile infection. Gastroenterology. 2017;152:1006. doi: 10.1016/S0016-5085(17)33415-7
        55. Bahl MI, Bergström A, Licht TR. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiol Lett. 2012;329:193-7. doi: 10.1111/j.1574-6968.2012.02523.x
        56. Sleight SC, Wigginton NS, Lenski RE. Increased susceptibility to repeated freeze-thaw cycles in Escherichia coli following long-term evolution in a benign environment. BMC Evol Biol. 2006;6:104. 
        doi: 10.1186/1471-2148-6-10457. Long C, Yu Y, Cui B, et al. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol.2018;18:37. doi: 10.1186/s12876-018-0766-2
        58. Shi Y, Dong Y, Huang W, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Public Library of Science ONE. 2016:11(6):e0157259. doi: 10.1371/ journal.pone.0157259
        59. Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016, 4: 610-3. doi: 10.1055/s-0042-105205
        60. Osman M, O’Brien K, Stoltzner Z, et al. Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis. 2016;3. doi: 10.1093/ofid/ofw172.1668
        61. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-8. doi: 10.1038/ajg.2013.59
        62. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic 
        review. J Clin Gastroenterol. 2014;48:693-702. doi: 10.1097/MCG.0000000000000046

        Авторы
        А.А. Якупова1, С.Р. Абдулхаков1,2, А.Г. Сафин1, И.М. Алиева1, Ю.В. Ослопова1, Р.А. Абдулхаков2

        1 ФГАОУ ВО «Казанский (Приволжский) федеральный университет», Казань, Россия;
        2 ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России, Казань, Россия


        ________________________________________________

        А.А. Iakupova1, S.R. Abdulkhakov1,2, A.G. Safin1, I.M. Alieva1, Ju.V. Oslopova1, R.A. Abdulkhakov2

        1 Kazan (Volga Region) Federal University, Kazan, Russia;
        2 Kazan State Medical University, Kazan, Russia


        Поделиться
        Назад к списку
        Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.

        Ключевые слова

        артериальная гипертензия дети артериальная гипертония лечение сахарный диабет COVID-19 ишемическая болезнь сердца диагностика беременность ожирение сердечно-сосудистые заболевания хроническая сердечная недостаточность рак молочной железы факторы риска метаболический синдром хроническая болезнь почек хроническая обструктивная болезнь легких качество жизни профилактика сахарный диабет 2-го типа фибрилляция предсердий инфаркт миокарда бесплодие антигипертензивная терапия прогноз сердечная недостаточность химиотерапия атеросклероз бронхиальная астма неалкогольная жировая болезнь печени таргетная терапия эффективность амлодипин нестероидные противовоспалительные препараты витамин D бактериальный вагиноз ревматоидный артрит гастроэзофагеальная рефлюксная болезнь реабилитация вирус папилломы человека безопасность коморбидность болезнь Крона атопический дерматит эндометриоз пробиотики эндотелиальная дисфункция язвенный колит инсулинорезистентность комбинированные оральные контрацептивы
        Узнавайте первым
        Подпишитесь, чтобы получать информацию о самых интересных событиях, последних новостях.
        Рассылка
        Новости
        Мероприятия
        Актуальные вебинары, конференции, семинары и т.д.
        Медиатека
        Записи вебинаров, подкасты, статьи и интервью.
        Библиотека
        Материалы для врачей-клиницистов:
        — Электронная...
        Наши контакты
        +7 (495) 098-03-59
        Заказать звонок
        Москва 125252, ул. Алабяна 13, корпус 1
        info@omnidoctor.ru
        Портал
        О портале
        История
        Лицензии
        Партнеры
        Реквизиты
        Об издательстве "Консилиум Медикум"
        Политика обработки ПД
        Пресс-центр
        Медиатека
        Библиотека
        Издания для врачей
        Издания для провизоров и фармацевтов
        Online-издания
        Мероприятия
        © 2025 Все права защищены.
        Подождите секунду, мы ищем Расширенный поиск
        Мы используем инструмент веб-аналитики Яндекс Метрика, который посредством обработки файлов «cookie» позволяет анализировать данные о посещаемости сайта, что помогает нам улучшить работу сайта, повысить его удобство и производительность. Соответственно, продолжая пользоваться сайтом, вы соглашаетесь на использование файлов «cookie» и их дальнейшую обработку сервисом Яндекс Метрика. Вы можете блокировать и (или) удалять файлы «cookie» в настройках своего веб-браузера.
        Я согласен(-на)